Vaishali Pharma Limited has informed the Exchange about change in Management
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vaishali Pharma Limited informed the exchange that shareholders approved two board changes through a postal ballot on April 24, 2025. First, the appointment of Mr. Bhaveshkumar Popatlal Upadhyay as a Non-Executive Independent Director was regularised, effective January 28, 2025, for a five-year term. Mr. Upadhyay, aged 54, holds an MBA in HR and has held senior leadership roles at Intas Pharmaceuticals and Cadila Pharmaceuticals. Second, Mr. Manish Bhagwandas Ved was re-appointed as an Independent Director for a second five-year term, also effective January 28, 2025. Mr. Ved, aged 59, is a commerce graduate with 25 years of experience as a property consultant. Both directors are not related to any existing directors on the board.
This is a routine governance update with no major red flags — independent director positions are being filled and renewed, which is standard for listed companies. Shareholders should see this as compliance housekeeping rather than any meaningful change to the company's direction or valuation.